Cargando…

Subcutaneous Administration of Bortezomib: Strategies to Reduce Injection Site Reactions

Bortezomib (Velcade) is approved by the FDA for IV or SC injection in select patients with multiple myeloma or mantle cell lymphoma. The SC route functions as an alternative to IV administration for patients with poor IV access. Learn about effective strategies used to reduce injection site reaction...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kurtin, Sandra, Knop, Carol S., Milliron, Todd
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Harborside Press 2012
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4093357/ https://www.ncbi.nlm.nih.gov/pubmed/25031973

Ejemplares similares

Subcutaneous Administration of Bortezomib: A Pilot Survey of Oncology Nurses
por: Martin, Jasmine R., et al.
Publicado: (2015)

Subcutaneous bortezomib for multiple myeloma treatment: patients’ benefits
por: Petrucci, Maria Teresa, et al.
Publicado: (2014)

Understanding and Minimising Injection-Site Pain Following Subcutaneous Administration of Biologics: A Narrative Review
por: St Clair-Jones, Anja, et al.
Publicado: (2020)

Injection-site reactions upon Kineret (anakinra) administration: experiences and explanations
por: Kaiser, Christina, et al.
Publicado: (2011)

Subcutaneous Administration of Bortezomib in Combination with Thalidomide and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma Patients
por: Wu, Shenghao, et al.
Publicado: (2015)

Subcutaneous Injection of Drugs: Literature Review of Factors Influencing Pain Sensation at the Injection Site
por: Usach, Iris, et al.
Publicado: (2019)

Reduced Weekly Subcutaneous Doses of Bortezomib in Combination with Cyclophosphamide and Dexamethasone for Newly Diagnosed Multiple Myeloma
por: Ashrafi, Farzaneh, et al.
Publicado: (2020)

The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection
por: Jin, Jing-fen, et al.
Publicado: (2015)

Clinical manifestations of intravitreal bortezomib injection
por: Nguyen, Chan, et al.
Publicado: (2020)

Bilateral injection-site granuloma by subcutaneous administration of luteinizing hormone-releasing hormone analogue: a case report
por: Kitazawa, Riko, et al.
Publicado: (2009)

Progress on the Application of Bortezomib and Bortezomib-Based Nanoformulations
por: Liu, Jianhao, et al.
Publicado: (2021)

Migration of Asbestos Fibres from Subcutaneous Injection Sites in Mice
por: Kanazawa, K., et al.
Publicado: (1970)

Subcutaneous vaccine administration – an outmoded practice
por: Cook, Ian F.
Publicado: (2020)

Early Reactions of the Subcutaneous Tissue to Repeated Injections of Carcinogens in Aqueous Solutions
por: Hooson, Jean, et al.
Publicado: (1971)

Cold Application on Bruising at the Subcutaneous Heparin Injection Site: A Systematic Review and Meta-Analysis
por: Amaniyan, Sara, et al.
Publicado: (2020)

Effect of Local Ketamine Subcutaneous Injection at the Incision Site in Reducing the Postoperative Pain Score after Transabdominal Hysterectomy
por: Eftekhar, Negar, et al.
Publicado: (2023)

Bortezomib
por: Rajappa, Senthil
Publicado: (2010)

Subcutaneous Injections
Publicado: (1871)

Review of Subcutaneous Wound Drainage in Reducing Surgical Site Infections after Laparotomy
por: Manzoor, B., et al.
Publicado: (2015)

REACTIONS OF RABBITS TO INTRACUTANEOUS INJECTIONS OF PNEUMOCOCCI AND THEIR PRODUCTS : III. REACTIONS AT THE SITE OF INJECTION
por: Julianelle, Louis A.
Publicado: (1930)

Glucose Levels at the Site of Subcutaneous Insulin Administration and Their Relationship to Plasma Levels
por: Lindpointner, Stefan, et al.
Publicado: (2010)

Interferon-gamma-induced local leukocytoclastic vasculitis at the subcutaneous injection site
por: Wang, Fang, et al.
Publicado: (2016)

Subcutaneous Bortezomib in Multiple Myeloma Patients Induces Similar Therapeutic Response Rates as Intravenous Application But It Does Not Reduce the Incidence of Peripheral Neuropathy
por: Minarik, Jiri, et al.
Publicado: (2015)

Practical Strategies for Management of Lenalidomide-Associated Cytopenias in Myelodysplastic Syndromes With del(5q)
por: Kurtin, Sandra E., et al.
Publicado: (2017)

Injection-Site Reaction Following 5-Azacitidine Injection
por: Jun, Hee Jin, et al.
Publicado: (2014)

Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis
por: Sidana, Surbhi, et al.
Publicado: (2017)

Tirzepatide-Induced Injection Site Reaction
por: Mizumoto, Junki
Publicado: (2023)

Feline Injection-Site Sarcoma and Other Adverse Reactions to Vaccination in Cats
por: Hartmann, Katrin, et al.
Publicado: (2023)

Saline Subcutaneous Injections
Publicado: (1890)

The Subcutaneous Injection of Quinine
Publicado: (1902)

The Subcutaneous Injection of Quinine
por: Moore, W. J.
Publicado: (1881)

The Subcutaneous Injection of Quinine
por: Cullen, P.
Publicado: (1871)

Subcutaneous Injections of Strychnine
Publicado: (1893)

Danger of Subcutaneous Injections
Publicado: (1865)

Danger of Subcutaneous Injections
Publicado: (1865)

Subcutaneous Injections of Iron
Publicado: (1891)

The Subcutaneous Injection of Ether
Publicado: (1882)

Bortezomib in Kidney Transplantation
por: Raghavan, Rajeev, et al.
Publicado: (2010)

The Sinus That Breeds Fungus: Subcutaneous Zygomycosis Caused by Basidiobolus ranarum at the Injection Site
por: Jayanth, S. T., et al.
Publicado: (2013)

Injection Site Tumours and Preceding Pathological Changes in rats Treated Subcutaneously with Surfactants and Carcinogens
por: Hooson, J., et al.
Publicado: (1973)

Cannot write session to /tmp/vufind_sessions/sess_h62e4fv0i7tk9p1tc02lsfclmh